Ovid Therapeutics Announces Phase 1 Results For Ov350

Reuters
2025.12.18 13:33
Dec 18 (Reuters) - Ovid Therapeutics Inc (OVID.O) : * OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350 * OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENT * OVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTS * OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026 Source text: Further company coverage: (OVID.O)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer